Cotinga Pharmaceuticals ROCE
Was ist das ROCE von Cotinga Pharmaceuticals?
ROCE von Cotinga Pharmaceuticals, Inc. ist 0.00%
Was ist die Definition von ROCE?
Die Kapitalerträge (ROCE) entsprechen einer Finanzkennzahl, die die Rentabilität eines Unternehmens und die Effizienz, mit der sein Kapital verwendet wird, misst.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE von Unternehmen in Health Care Sektor auf TSXV im Vergleich zu Cotinga Pharmaceuticals
Was macht Cotinga Pharmaceuticals?
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
Unternehmen mit roce ähnlich Cotinga Pharmaceuticals
- Omega Alpha Spac hat ROCE von -0.01%
- The Gap hat ROCE von -0.01%
- Elemental Royalties Ltd hat ROCE von -0.01%
- Auburn National Bancorp hat ROCE von -0.01%
- Galaxy Digital hat ROCE von -0.01%
- The Gap hat ROCE von -0.01%
- Cotinga Pharmaceuticals hat ROCE von 0.00%
- Tejon Ranch Co hat ROCE von 0.01%
- Glen Burnie Bancorp hat ROCE von 0.02%
- MSP Steel & Power hat ROCE von 0.02%
- TTL Beteiligungs- und Grundbesitz-AG hat ROCE von 0.03%
- First Foundation Inc hat ROCE von 0.03%
- FirstMark Horizon Acquisition hat ROCE von 0.03%